Trials / Completed
CompletedNCT02671461
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986141 | |
| DRUG | Aspirin | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-04-25
- Primary completion
- 2017-03-31
- Completion
- 2017-03-31
- First posted
- 2016-02-02
- Last updated
- 2018-12-14
- Results posted
- 2018-06-12
Locations
33 sites across 2 countries: United States, Japan
Source: ClinicalTrials.gov record NCT02671461. Inclusion in this directory is not an endorsement.